Radiomics Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma from Hepatocellular Carcinoma: A Multi-Center Study
DOI: https://doi.org/10.2147/JHC.S406648
2023-06-02
Journal of Hepatocellular Carcinoma
Abstract:Le Guo, 1, &ast Xijun Li, 2, &ast Chao Zhang, 3, &ast Yang Xu, 4 Lujun Han, 5 Ling Zhang 1 1 Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China; 2 Key Laboratory of Hunan Province for Internet of Things and Information Security, Xiangtan University, Xiangtan, Hunan Province, People's Republic of China; 3 Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China; 4 Department of Interventional, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China; 5 Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ling Zhang, Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China, Tel +86-2062786561, Email Lujun Han, Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China, Tel +86-2087342125, Email Purpose: To explore whether texture features based on magnetic resonance can distinguish diseases combined hepatocellular-cholangiocarcinoma (cHCC-CC) from hepatocellular carcinoma (HCC) before operation. Methods: The clinical baseline data and MRI information of 342 patients with pathologically diagnosed cHCC-CC and HCC in two medical centers were collected. The data were divided into the training set and the test set at a ratio of 7:3. MRI images of tumors were segmented with ITK-SNAP software, and python open-source platform was used for texture analysis. Logistic regression as the base model, mutual information (MI) and Least Absolute Shrinkage and Selection Operator (LASSO) regression were used to select the most favorable features. The clinical, radiomics, and clinic-radiomics model were constructed based on logistic regression. The model's effectiveness was comprehensively evaluated by the receiver operating characteristic (ROC) curve, area under the curve (AUC), sensitivity, specificity, and Youden index which is the main, and the model results were exported by SHapley Additive exPlanations (SHAP). Results: A total of 23 features were included. Among all models, the arterial phase-based clinic-radiomics model showed the best performance in differentiating cHCC-CC from HCC before an operation, with the AUC of the test set being 0.863 (95% CI: 0.782 to 0.923), the specificity and sensitivity being 0.918 (95% CI: 0.819 to 0.973) and 0.738 (95% CI: 0.580 to 0.861), respectively. SHAP value results showed that the RMS was the most important feature affecting the model. Conclusion: Clinic-radiomics model based on DCE-MRI may be useful to distinguish cHCC-CC from HCC in a preoperative setting, especially in the arterial phase, and RMS has the greatest impact. Keywords: magnetic resonance, radiomics, machine learning, primary liver cancer, differential diagnosis As the rarest pathological type of primary liver cancer, combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) accounts for about 0.4–14.2% of all primary liver carcinomas. 1 It displays a mixture of histological characteristics of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and has the differentiation characteristics of hepatocytes and bile duct cells. At present, where cHCC-CC originates from remains controversial, with several studies supporting that liver progenitor cells are the origin of cHCC-CC. 1–4 While some scholars hold that HCC and ICC components in cHCC-CC may come from HCC or common stem cells, which then differentiate into hepatocytes and bile duct epithelial cells. 3,5 HCC is the primary liver cancer with the highest incidence. When it contains ICC, it conforms to type C cHCC-CC, 6 i.e, HCC and ICC are located within the same mass. Yet, these two diseases differ in their prognosis. The survival rate of HCC after liver transplantation or surgical resection is higher than that of cHCC-CC. 7–14 Transarterial chemoembolization (TACE) is a common treatment for HCC patients whose tumor is unresectable or inability to tolerate surgery due to medical comorbidities, even those who want to be exempt from the pain of surgery. However, this -Abstract Truncated-
oncology